Retatrutide 20MG

Product Overview

Retatrutide 20MG is a synthetic peptide research material associated with concurrent GLP-1, GIP and glucagon-receptor agonism, supplied as white to off-white lyophilised powder in a 20mg catalogue presentation (SKU RT20). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

Retatrutide has been investigated as a multi-receptor agonist in receptor-pharmacology, metabolic-signalling and clinical-development studies. Published work distinguishes molecule-level findings from the identity, purity and performance of any independently supplied batch.

Identity and Specifications

• Product: Retatrutide 20MG
• SKU: RT20
• Format: White to off-white lyophilised powder
• Synonyms: LY3437943, Triple-Receptor Agonist
• Catalogue purity specification: ≥99%
• CAS number: 2381089-83-2
• Molecular formula: C221H342N46O68
• Molecular weight: 4731 g/mol
• Amount: 20mg

Catalogue Distinction

This is the 20mg listing for this identity. The related Retatrutide 10mg listing has a different labelled amount or volume and a separate SKU. The amount difference is not a dose recommendation. Unless a batch certificate states otherwise, the scientific identity and research limitations are shared while the quantity supplied differs.

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• GLP-1, GIP and glucagon-receptor signalling
• receptor selectivity and downstream second-messenger responses
• energy and substrate metabolism in controlled models
• pharmacokinetic and clinical-development study design

Evidence Quality and Limitations

Evidence includes receptor and animal studies, phase 2 human trials and ongoing phase 3 programmes. Trial findings concern sponsor-manufactured investigational material and cannot be transferred to this ExtolX vial without product-specific validation.

Regulatory Context

At the review date, ClinicalTrials.gov lists active phase 3 retatrutide studies. Retatrutide remains an investigational substance; this ExtolX product is not an authorised medicine or a clinical-trial product.

Storage and Handling

Before reconstitution: Keep the lyophilised vial sealed, dry and protected from light at −20°C or below, subject to the batch-specific supplier documentation. Published retatrutide reference-material data support frozen storage, but the exact salt and formulation of this ExtolX batch have not been confirmed. Allow a cold vial to reach room temperature before opening to reduce condensation.

After reconstitution: Stability depends on the exact salt or formulation, solvent, concentration, pH and container. Prepare only what the validated method requires. If that method supports frozen storage, use single-use aliquots and avoid repeated freeze–thaw cycles. Use clean laboratory technique, avoid vigorous agitation, and record the preparation and storage history. No numerical solution shelf life has been verified for this ExtolX batch.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• MedChemExpress: Retatrutide storage reference
• PubMed: Phase 2 retatrutide obesity trial
• PubMed: Retatrutide in type 2 diabetes
• PubMed: Liver-fat substudy
• ClinicalTrials.gov: TRIUMPH-3 retatrutide phase 3 study

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.